Bioinformatics for cancer immunology and immunotherapy

Cancer Immunology, Immunotherapy

Volumn 61, Issue 11, 2012, Pages 1885-1903

  Charoentong, Pornpimol ^a   Angelova, Mihaela ^a   Efremova, Mirjana ^a   Gallasch, Ralf ^a   Hackl, Hubert ^a   Galon, Jerome ^b   Trajanoski, Zlatko ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b CENTRE DE RECHERCHE DES CORDELIERS   (France)

Author keywords

Bioinformatics; Databases; Epitope prediction; Immunotherapy; Mathematical modeling; Next generation sequencing

Indexed keywords

DNA; EPITOPE; MICRORNA;

AMINO ACID SUBSTITUTION; ANTIGEN DETECTION; ANTIGEN EXPRESSION; BIOINFORMATICS; CANCER GENETICS; CANCER GROWTH; CANCER IMMUNOLOGY; CANCER IMMUNOTHERAPY; CANCER PROGNOSIS; CELL INTERACTION; CLONAL EVOLUTION; COMPARATIVE GENOMIC HYBRIDIZATION; COMPUTER PREDICTION; COPY NUMBER VARIATION; CYTOKINE RELEASE; DATA ANALYSIS; DATA BASE; EPIGENETICS; EXOME; GENE EXPRESSION; GENE MUTATION; GENETIC PROCEDURES; GENOME ANALYSIS; HUMAN; IMMUNOCOMPETENT CELL; MATHEMATICAL MODEL; MEDICAL INFORMATION SYSTEM; NEXT GENERATION SEQUENCING; PRIORITY JOURNAL; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; SOMATIC MUTATION;

B-LYMPHOCYTES; BASE SEQUENCE; COMPUTATIONAL BIOLOGY; DATABASES, GENETIC; EPITOPES; HUMANS; IMMUNOTHERAPY; MODELS, BIOLOGICAL; MOLECULAR SEQUENCE DATA; NEOPLASMS; SEQUENCE ANALYSIS, DNA; T-LYMPHOCYTES;

EID: 84871030732     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-012-1354-x     Document Type: Review

References (169)

1. Kirkwood JM, Butterfield LH, Tarhini AA, Zarour H, Kalinski P, Ferrone S (2012) Immunotherapy of cancer in 2012. CA Cancer J Clinic. doi:10.3322/caac. 20132
2. Finn OJ (2008) Cancer immunology. N Engl J Med 358(25): 2704-2715
3. Scanlan MJ, Chen YT, Williamson B, Gure AO, Stockert E, Gordan JD, Türeci O, Sahin U, Pfreundschuh M, Old LJ (1998) Characterization of human colon cancer antigens recognized by autologous antibodies. Int J Cancer 76(5):652-658
4. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD (2002) Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 3(11):991-998
5. Dunn GP, Old LJ, Schreiber RD (2004) The immunobiology of cancer immunosurveillance and immunoediting. Immunity 21(2):137-148
6. Dunn GP, Old LJ, Schreiber RD (2004) The three Es of cancer immunoediting. Annu Rev Immunol 22:329-360
7. Galon J, Costes A, Sanchez-Cabo F et al (2006) Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313(5795):1960-1964
8. Pagès F, Berger A, Camus M et al (2005) Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med 353(25):2654-2666
9. Mlecnik B, Tosolini M, Kirilovsky A et al (2011) Histopathologic-based prognostic factors of colorectal cancers are associated with the state of the local immune reaction. J Clin Oncol 29(6):610-618
10. Brahmer JR, Tykodi SS, Chow LQM et al (2012) Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 366(26):2455-2465
11. Topalian SL, Hodi FS, Brahmer JR et al (2012) Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366(26):2443-2454
12. Dougan M, Dranoff G (2009) Immune therapy for cancer. Annu Rev Immunol 27:83-117
13. Coulie PG, Lehmann F, Lethé B, Herman J, Lurquin C, Andrawiss M, Boon T (1995) A mutated intron sequence codes for an antigenic peptide recognized by cytolytic T lymphocytes on a human melanoma. Proc Natl Acad Sci USA 92(17):7976-7980
14. Chen YT, Scanlan MJ, Sahin U, Türeci O, Gure AO, Tsang S, Williamson B, Stockert E, Pfreundschuh M, Old LJ (1997) A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc Natl Acad Sci USA 94(5):1914-1918
15. Castle JC, Kreiter S, Diekmann J et al (2012) Exploiting the mutanome for tumor vaccination. Cancer Res 72(5):1081-1091
16. Gadaleta E, Lemoine NR, Chelala C (2011) Online resources of cancer data: barriers, benefits and lessons. Brief Bioinform 12(1):52-63
17. Hudson TJ, Anderson W, Artez A et al (2010) International network of cancer genome projects. Nature 464(7291):993-998
18. Mailman MD, Feolo M, Jin Y et al (2007) The NCBI dbGaP database of genotypes and phenotypes. Nat Genet 39(10): 1181-1186
19. Forbes SA, Bindal N, Bamford S et al. (2011) COSMIC: mining complete cancer genomes in the catalogue of somatic mutations in cancer. Nucleic Acids Res 39(database issue):D945-D950
20. Rhodes DR, Kalyana-Sundaram S, Mahavisno V et al (2007) Oncomine 3.0: genes, pathways, and networks in a collection of 18,000 cancer gene expression profiles. Neoplasia 9(2):166-180
21. Futreal PA, Coin L, Marshall M, Down T, Hubbard T, Wooster R, Rahman N, Stratton MR (2004) A census of human cancer genes. Nat Rev Cancer 4(3):177-183
22. Strausberg RL (2001) The cancer genome anatomy project: new resources for reading the molecular signatures of cancer. J Pathol 195(1):31-40
23. Buetow KH, Klausner RD, Fine H, Kaplan R, Singer DS, Strausberg RL (2002) Cancer molecular analysis project: weaving a rich cancer research tapestry. Cancer Cell 1(4):315-318
24. Kakazu KK, Cheung LWK, Lynne W (2004) The cancer biomedical informatics grid (caBIG): pioneering an expansive network of information and tools for collaborative cancer research. Hawaii Med J 63(9):273-275
25. caBIG Strategic Planning Workspace (2007) The cancer biomedical informatics grid (caBIG): infrastructure and applications for a worldwide research community. Stud Health Technol Inform 129(Pt 1):330-334
26. Li H, He Y, Ding G, Wang C, Xie L, Li Y (2010) dbDEPC: a database of differentially expressed proteins in human cancers. Nucleic Acids Res 38(Database issue):D658-D664
27. Zhu J, Sanborn JZ, Benz S et al (2009) The UCSC cancer genomics browser. Nat Methods 6(4):239-240
28. Edgar R, Domrachev M, Lash AE (2002) Gene expression omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res 30(1):207-210
29. Sherry ST, Ward MH, Kholodov M, Baker J, Phan L, Smigielski EM, Sirotkin K (2001) dbSNP: the NCBI database of genetic variation. Nucleic Acids Res 29(1):308-311
30. Thorvaldsdóttir H, Robinson JT, Mesirov JP (2012) Integrative genomics viewer (IGV): high-performance genomics data visualization and exploration. Brief Bioinform. doi:10.1093/bib/ bbs017
31. Gonzalez-Angulo AM, Hennessy BTJ, Mills GB (2010) Future of personalized medicine in oncology: a systems biology approach. J Clin Oncol 28(16):2777-2783
32. Virtanen C, Woodgett J (2008) Clinical uses of microarrays in cancer research. Methods Mol Med 141:87-113
33. Lu J, Getz G, Miska EA et al (2005) MicroRNA expression profiles classify human cancers. Nature 435(7043):834-838
34. Michels E, De Preter K, Van Roy N, Speleman F (2007) Detection of DNA copy number alterations in cancer by array comparative genomic hybridization. Genet Med 9(9): 574-584
35. Shlien A, Malkin D (2010) Copy number variations and cancer susceptibility. Curr Opin Oncol 22(1):55-63
36. Vogelstein B, Kinzler KW (2002) The genetic basis of human cancer. McGraw-Hill, Medical Pub. Division, New York
37. Ellis L, Atadja PW, Johnstone RW (2009) Epigenetics in cancer: targeting chromatin modifications. Mol Cancer Ther 8(6):1409-1420
38. Chin L, Hahn WC, Getz G, Meyerson M (2011) Making sense of cancer genomic data. Genes Dev 25(6):534-555
39. Cheon D-J, Orsulic S (2011) Mouse models of cancer. Annu Rev Pathol 6:95-119
40. Goya R, Sun MGF, Morin RD et al (2010) SNVMix: predicting single nucleotide variants from next-generation sequencing of tumors. Bioinformatics 26(6):730-736
41. Huang J, Honda W (2006) CED: a conformational epitope database. BMC Immunol 7(1):7
42. Nakamura Y, Komiyama T, Furue M, Gojobori T, Akiyama Y (2010) CIG-DB: the database for human or mouse immunoglobulin and T cell receptor genes available for cancer studies. BMC Bioinform 11:398
43. Mundstein AS, Camargo A, Simpson AJ, Chen Y-T (2012) CTpedia. In: CTDatabase. http://www.cta.lncc.br/. Accessed 10 Jul 2012
44. Zhang GL, Lin HH, Keskin DB, Reinherz EL, Brusic V (2011) Dana-Farber repository for machine learning in immunology. J Immunol Methods 374(1-2):18-25
45. Reche PA, Zhang H, Glutting J-P, Reinherz EL (2005) EPIMHC: a curated database of MHC-binding peptides for customized computational vaccinology. Bioinformatics 21(9):2140-2141
46. Salimi N, Fleri W, Peters B, Sette A (2012) The immune epitope database: a historical retrospective of the first decade. Immunology. doi:10.1111/j.1365- 2567.2012.03611.x
47. Lata S, Bhasin M, Raghava GPS (2009) MHCBN 4.0: a database of MHC/TAP binding peptides and T-cell epitopes. BMC Res Notes 2:61
48. van der Bruggen P, Stroobant V, Vigneron N, Van den Eynde B (2012) Cancer immunity -peptide database. In: PeptideDatabase. http://archive.cancerimmunity. org/peptidedatabase/Tcellepitop es.htm. Accessed 10 Jul 2012
49. Rammensee H, Bachmann J, Emmerich NP, Bachor OA, Stevanović S (1999) SYFPEITHI: database for MHC ligands and peptide motifs. Immunogenetics 50(3-4):213-219
50. Saha S, Bhasin M, Raghava GPS (2005) Bcipep: a database of B-cell epitopes. BMC Genomics 6:79
51. Wang X, Zhao H, Xu Q et al. (2006) HPtaa database-potential target genes for clinical diagnosis and immunotherapy of human carcinoma. Nucleic Acids Res 34(database issue):D607-D612
52. Koschmieder A, Zimmermann K, Trissl S, Stoltmann T, Leser U (2012) Tools for managing and analyzing microarray data. Brief Bioinform 13(1):46-60
53. Hackl H, Stocker G, Charoentong P, Mlecnik B, Bindea G, Galon J, Trajanoski Z (2010) Information technology solutions for integration of biomolecular and clinical data in the identification of new cancer biomarkers and targets for therapy. Pharmacol Ther 128(3):488-498
54. Chakravarti B, Mallik B, Chakravarti DN (2010) Proteomics and systems biology: application in drug discovery and development. Methods Mol Biol 662:3-28
55. Chang H-W, Chuang L-Y, Tsai M-T, Yang C-H (2012) The importance of integrating SNP and cheminformatics resources to pharmacogenomics. Curr Drug Metab 13:991-999
56. Costa JL, Meijer G, Ylstra B, Caldas C (2008) Array comparative genomic hybridization copy number profiling: a new tool for translational research in solid malignancies. Semin Radiat Oncol 18(2):98-104
57. Garber M, Grabherr MG, Guttman M, Trapnell C (2011) Computational methods for transcriptome annotation and quantification using RNA-Seq data. Nat Methods 8(6):469-477
58. Lam HYK, Clark MJ, Chen R et al (2012) Performance comparison of whole-genome sequencing platforms. Nat Biotechnol 30(6):562
59. Asmann YW, Middha S, Hossain A et al (2012) TREAT: a bioinformatics tool for variant annotations and visualizations in targeted and exome sequencing data. Bioinformatics 28(2): 277-278
60. Fischer M, Snajder R, Pabinger S, Dander A, Schossig A, Zschocke J, Trajanoski Z, Stocker G (2012) SIMPLEX: cloudenabled pipeline for the comprehensive analysis of exome sequencing data. PLoS One (in press)
61. Goecks J, Nekrutenko A, Taylor J (2010) Galaxy: a comprehensive approach for supporting accessible, reproducible, and transparent computational research in the life sciences. Genome Biol 11(8):R86
62. Hull D, Wolstencroft K, Stevens R, Goble C, Pocock MR, Li P, Oinn T (2006) Taverna: a tool for building and running workflows of services. Nucleic Acids Res 34(Web Server issue): W729-W732
63. Rex DE, Ma JQ, Toga AW (2003) The LONI pipeline processing environment. Neuroimage 19(3):1033-1048
64. Starck SR, Shastri N (2011) Non-conventional sources of peptides presented by MHC class I. Cell Mol Life Sci 68(9):1471-1479
65. Mester G, Hoffmann V, Stevanović S (2011) Insights into MHC class I antigen processing gained from large-scale analysis of class I ligands. Cell Mol Life Sci 68(9):1521-1532
66. Lundegaard C, Hoof I, Lund O, Nielsen M (2010) State of the art and challenges in sequence based T-cell epitope prediction. Immunome Res 6(Suppl 2):S3
67. Lundegaard C, Lund O, Buus S, Nielsen M (2010) Major histocompatibility complex class I binding predictions as a tool in epitope discovery. Immunology 130(3):309-318
68. Lafuente EM, Reche PA (2009) Prediction of MHC-peptide binding: a systematic and comprehensive overview. Curr Pharm Des 15(28):3209-3220
69. Parker KC, Bednarek MA, Coligan JE (1994) Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains. J Immunol 152(1):163-175
70. Warren RL, Holt RA (2010) A census of predicted mutational epitopes suitable for immunologic cancer control. Hum Immunol 71(3):245-254
71. Segal NH, Parsons DW, Peggs KS, Velculescu V, Kinzler KW, Vogelstein B, Allison JP (2008) Epitope landscape in breast and colorectal cancer. Cancer Res 68(3):889-892
72. Xu W, Li H-Z, Liu J-J, Guo Z, Zhang B-F, Chen F-F, Pei D-S, Zheng J-N (2011) Identification of HLA-A.*0201-restricted cytotoxic T lymphocyte epitope from proliferating cell nuclear antigen. Tumour Biol 32(1):63-69
73. AsemissenAM,Haase D, Stevanovic S, Bauer S, BusseA, Thiel E, Rammensee H-G, Keilholz U, Scheibenbogen C (2009) Identification of an immunogenic HLA-A.*0201-binding T-cell epitope of the transcription factor PAX2. J Immunother 32(4):370-375
74. SYFPEITHI. http://www.syfpeithi.de/. Accessed 17 Aug 2012
75. Peters B, Sette A (2005) Generating quantitative models describing the sequence specificity of biological processes with the stabilized matrix method. BMC Bioinform 6:132
76. Lundegaard C, Lamberth K, Harndahl M, Buus S, Lund O, Nielsen M (2008) NetMHC-3.0: accurate web accessible predictions of human, mouse and monkey MHC class I affinities for peptides of length 8-11. Nucleic Acids Res 36(Web Server issue):W509-W512
77. Peters B, Bui H-H, Frankild S et al (2006) A community resource benchmarking predictions of peptide binding to MHC-I molecules. PLoS Comput Biol 2(6):e65
78. Lin HH, Ray S, Tongchusak S, Reinherz EL, Brusic V (2008) Evaluation of MHC class I peptide binding prediction servers: applications for vaccine research. BMC Immunol 9:8
79. Larsen MV, Lundegaard C, Lamberth K, Buus S, Lund O, Nielsen M (2007) Large-scale validation of methods for cytotoxic T-lymphocyte epitope prediction. BMC Bioinform 8:424
80. Nielsen M, Justesen S, Lund O, Lundegaard C, Buus S (2010) NetMHCIIpan-2.0 -improved pan-specific HLA-DR predictions using a novel concurrent alignment and weight optimization training procedure. Immunome Res 6:9
81. Zhang L, Chen Y, Wong H-S, Zhou S, Mamitsuka H, Zhu S (2012) TEPITOPEpan: extending TEPITOPE for peptide binding prediction covering over 700 HLA-DR molecules. PLoS One 7(2):e30483
82. Stranzl T, Larsen MV, Lundegaard C, Nielsen M (2010) Net-CTLpan: pan-specific MHC class I pathway epitope predictions. Immunogenetics 62(6):357-368
83. Zhang H, Lundegaard C, Nielsen M (2009) Pan-specific MHC class I predictors: a benchmark of HLA class I pan-specific prediction methods. Bioinformatics 25(1):83-89
84. EL-Manzalawy Y, Honavar V (2010) Recent advances in B-cell epitope prediction methods. Immunome Res 6(Suppl 2):S2
85. Larsen JEP, Lund O, Nielsen M (2006) Improved method for predicting linear B-cell epitopes. Immunome Res 2:2
86. Saha S, Raghava GPS (2006) Prediction of continuous B-cell epitopes in an antigen using recurrent neural network. Proteins Struct Funct Bioinform 65(1):40-48
87. Ansari HR, Raghava GP (2010) Identification of conformational B-cell Epitopes in an antigen from its primary sequence. Immunome Res 6:6
88. Ponomarenko J, Bui H-H, Li W, Fusseder N, Bourne PE, Sette A, Peters B (2008) ElliPro: a new structure-based tool for the prediction of antibody epitopes. BMC Bioinform 9:514
89. Eswar N, Webb B, Marti-Renom MA, Madhusudhan MS, Eramian D, Shen M-Y, Pieper U, Sali A (2007) Comparative protein structure modeling using MODELLER. Curr Protoc Protein Sci Chapter 2:Unit 2.9
90. Pe'er D, Hacohen N (2011) Principles and strategies for developing network models in cancer. Cell 144(6):864-873
91. Wu G, Feng X, Stein L (2010) A human functional protein interaction network and its application to cancer data analysis. Genome Biol 11(5):R53
92. Rhodes DR, Tomlins SA, Varambally S, Mahavisno V, Barrette T, Kalyana-Sundaram S, Ghosh D, Pandey A, Chinnaiyan AM (2005) Probabilistic model of the human protein-protein interaction network. Nat Biotechnol 23(8):951-959
93. Hwang D, Rust AG, Ramsey S et al (2005) A data integration methodology for systems biology. Proc Natl Acad Sci USA 102(48):17296-17301
94. Cline MS, Smoot M, Cerami E et al (2007) Integration of biological networks and gene expression data using Cytoscape. Nat Protoc 2(10):2366-2382
95. Gehlenborg N, O'Donoghue SI, Baliga NS et al (2010) Visualization of omics data for systems biology. Nat Methods 7(3 Suppl):S56-S68
96. Basso K, Margolin AA, Stolovitzky G, Klein U, Dalla-Favera R, Califano A (2005) Reverse engineering of regulatory networks in human B cells. Nat Genet 37(4):382-390
97. Wang K, Saito M, Bisikirska BC et al (2009) Genome-wide identification of post-Translational modulators of transcription factor activity in human B cells. Nat Biotechnol 27(9):829-839
98. Ideker T, Ozier O, Schwikowski B, Siegel AF (2002) Discovering regulatory and signalling circuits in molecular interaction networks. Bioinformatics 18(Suppl 1):S233-S240
99. Kreeger PK, Lauffenburger DA (2010) Cancer systems biology: a network modeling perspective. Carcinogenesis 31(1):2-8
100. Dutta B, Pusztai L, Qi Y et al (2012) A network-based, integrative study to identify core biological pathways that drive breast cancer clinical subtypes. Br J Cancer 106(6):1107-1116
101. Mlecnik B, Tosolini M, Charoentong P et al (2010) Biomolecular network reconstruction identifies T-cell homing factors associated with survival in colorectal cancer. Gastroenterology 138(4):1429-1440
102. Pujana MA, Han J-DJ, Starita LM et al (2007) Network modeling links breast cancer susceptibility and centrosome dysfunction. Nat Genet 39(11):1338-1349
103. Tomlins SA, Mehra R, Rhodes DR et al (2007) Integrative molecular concept modeling of prostate cancer progression. Nat Genet 39(1):41-51
104. Baudot A, de la Torre V, Valencia A (2010) Mutated genes, pathways and processes in tumours. EMBO Rep 11(10):805-810
105. Reis-Filho JS (2009) Next-generation sequencing. Breast Cancer Res 11(Suppl 3):S12
106. Eifert C, Powers RS (2012) From cancer genomes to oncogenic drivers, tumour dependencies and therapeutic targets. Nat Rev Cancer 12(8):572-578
107. Curtis C, Shah SP, Chin S-F et al (2012) The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature 486(7403):346-352
108. Stephens PJ, Tarpey PS, Davies H et al (2012) The landscape of cancer genes and mutational processes in breast cancer. Nature 486(7403):400-404
109. Carter SL, Cibulskis K, Helman E et al (2012) Absolute quantification of somatic DNA alterations in human cancer. Nat Biotechnol 30(5):413-421
110. Nik-Zainal S, Alexandrov LB, Wedge DC et al (2012) Mutational processes molding the genomes of 21 breast cancers. Cell 149(5):979-993
111. Nik-Zainal S, Van Loo P, Wedge DC et al (2012) The life history of 21 breast cancers. Cell 149(5):994-1007
112. The Cancer Genome Atlas Research Network (2011) Integrated genomic analyses of ovarian carcinoma. Nature 474(7353): 609-615
113. The Cancer Genome Atlas Research Network (2008) Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455(7216):1061-1068
114. Shah SP, Roth A, Goya R et al (2012) The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature 486(7403):395-399
115. Mardis ER (2012) Genome sequencing and cancer. Curr Opin Genet Dev 22(3):245-250
116. Mardis ER, Ding L, Dooling DJ et al (2009) Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med 361(11):1058-1066
117. Walter MJ, Shen D, Ding L et al (2012) Clonal architecture of secondary acute myeloid leukemia. N Engl J Med 366(12): 1090-1098
118. Cerami E, Demir E, Schultz N, Taylor BS, Sander C (2010) Automated network analysis identifies core pathways in glioblastoma. PLoS ONE 5(2):e8918
119. Ciriello G, Cerami E, Sander C, Schultz N (2012) Mutual exclusivity analysis identifies oncogenic network modules. Genome Res 22(2):398-406
120. Vaske CJ, Benz SC, Sanborn JZ, Earl D, Szeto C, Zhu J, Haussler D, Stuart JM (2010) Inference of patient-specific pathway activities from multi-dimensional cancer genomics data using PARADIGM. Bioinformatics 26(12):i237-i245
121. Carter H, Chen S, Isik L, Tyekucheva S, Velculescu VE, Kinzler KW, Vogelstein B, Karchin R (2009) Cancer-specific highthroughput annotation of somatic mutations: computational prediction of drivermissensemutations.CancerRes 69(16):6660-6667
122. Beroukhim R, Getz G, Nghiemphu L et al (2007) Assessing the significance of chromosomal aberrations in cancer: methodology and application to glioma. Proc Natl Acad Sci USA 104(50): 20007-20012
123. Koboldt DC, Zhang Q, Larson DE, Shen D, McLellan MD, Lin L, Miller CA, Mardis ER, Ding L, Wilson RK (2012) VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing. Genome Res 22(3):568-576
124. Akavia UD, Litvin O, Kim J, Sanchez-Garcia F, Kotliar D, Causton HC, Pochanard P, Mozes E, Garraway LA, Pe'er D (2010) An integrated approach to uncover drivers of cancer. Cell 143(6):1005-1017
125. Mathew JP, Taylor BS, Bader GD, Pyarajan S, Antoniotti M, Chinnaiyan AM, Sander C, Burakoff SJ, Mishra B (2007) From bytes to bedside: data integration and computational biology for translational cancer research. PLoS Comput Biol 3(2):e12
126. Ascierto ML, Kmieciak M, Idowu MO et al (2012) A signature of immune function genes associated with recurrence-free survival in breast cancer patients. Breast Cancer Res Treat 131(3):871-880
127. Knudson AG Jr (1971) Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci USA 68(4):820-823
128. Nowell PC (1976) The clonal evolution of tumor cell populations. Science 194(4260):23-28
129. Durrett R, Foo J, Leder K, Mayberry J, Michor F (2011) Intratumor heterogeneity in evolutionary models of tumor progression. Genetics 188(2):461-477
130. Bozic I, Antal T, Ohtsuki H, Carter H, Kim D, Chen S, Karchin R, Kinzler KW, Vogelstein B, Nowak MA (2010) Accumulationof driver and passenger mutations during tumor progression. Proc Natl Acad Sci USA 107(43):18545-18550
131. Nowak MA, Michor F, Komarova NL, Iwasa Y (2004) Evolutionary dynamics of tumor suppressor gene inactivation. Proc Natl Acad Sci USA 101(29):10635-10638
132. Beerenwinkel N, Antal T, Dingli D, Traulsen A, Kinzler KW, Velculescu VE, Vogelstein B, Nowak MA (2007) Genetic progression and the waiting time to cancer. PLoS Comput Biol 3(11):e225
133. Martens EA, Kostadinov R, Maley CC, Hallatschek O (2011) Spatial structure increases the waiting time for cancer. New J Phys 13:115014
134. Haeno H, Iwasa Y, Michor F (2007) The evolution of two mutations during clonal expansion. Genetics 177(4):2209-2221
135. Attolini CS-O, Michor F (2009) Evolutionary theory of cancer. Ann N Y Acad Sci 1168:23-51
136. Schweinsberg J (2008) The waiting time for m mutations. Electron J Probab 13(52):1442-1478
137. Durrett R, Schmidt D, Schweinsberg J (2009) A waiting time problem arising from the study of multi-stage carcinogenesis. Ann Appl Probab 19(2):676-718
138. Attolini CS-O, Cheng Y-K, Beroukhim R, Getz G, Abdel-Wahab O, Levine RL, Mellinghoff IK, Michor F (2010) A mathematical framework to determine the temporal sequence of somatic genetic events in cancer. Proc Natl Acad Sci USA 107(41):17604-17609
139. Sprouffske K, Pepper JW, Maley CC (2011) Accurate reconstruction of the temporal order of mutations in neoplastic progression. Cancer Prev Res (Phila) 4(7):1135-1144
140. Gerstung M, Eriksson N, Lin J, Vogelstein B, Beerenwinkel N (2011) The temporal order of genetic and pathway alterations in tumorigenesis. PLoS ONE 6(11):e27136
141. Michor F, Nowak MA, Iwasa Y (2006) Evolution of resistance to cancer therapy. Curr Pharm Des 12(3):261-271
142. Komarova N (2006) Stochastic modeling of drug resistance in cancer. J Theor Biol 239(3):351-366
143. Diaz LA Jr, Williams RT, Wu J et al (2012) The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature 486(7404):537-540
144. Vincent TL, Gatenby RA (2008) An evolutionary model for initiation, promotion, and progression in carcinogenesis. Int J Oncol 32(4):729-737
145. Gatenby RA, Vincent TL (2003) Application of quantitative models from population biology and evolutionary game theory to tumor therapeutic strategies. Mol Cancer Ther 2(9):919-927
146. Gatenby RA, Gillies RJ (2008) A microenvironmental model of carcinogenesis. Nat Rev Cancer 8(1):56-61
147. Lee H-O, Silva AS, Concilio S, Li Y-S, Slifker M, Gatenby RA, Cheng JD (2011) Evolution of tumor invasiveness: the adaptive tumor microenvironment landscape model. Cancer Res 71(20):6327-6337
148. Bozic I, Allen B, Nowak MA (2012) Dynamics of targeted cancer therapy. Trends Mol Med 18(6):311-316
149. Materi W, Wishart DS (2007) Computational systems biology in drug discovery and development: methods and applications. Drug Discov Today 12(7-8):295-303
150. Narang V, Decraene J, Wong S-Y, Aiswarya BS, Wasem AR, Leong SR, Gouaillard A (2012) Systems immunology: a survey of modeling formalisms, applications and simulation tools. Immunol Res 53(1-3):251-265
151. Eftimie R, Bramson JL, Earn DJD (2011) Interactions between the immune system and cancer: a brief review of non-spatial mathematical models. Bull Math Biol 73(1):2-32
152. Materi W, Wishart DS (2007) Computational systems biology in cancer: modeling methods and applications. Gene Regul Syst Bio 1:91-110
153. Kronik N, Kogan Y, Schlegel PG, Wölfl M (2012) Improving T-cell immunotherapy for melanoma through a mathematically motivated strategy: efficacy in numbers? J Immunother 35(2):116-124
154. June CH (2007) Adoptive T cell therapy for cancer in the clinic. J Clin Invest 117(6):1466-1476
155. Disis ML, Bernhard H, Jaffee EM (2009) Use of tumour-responsive T cells as cancer treatment. Lancet 373(9664):673-683
156. Kolev M, Kozowska E, Lachowicz M (2005) A mathematical model for single cell cancer-Immune system dynamics. Mathematical and Computer Modelling. Elsevier Science, pp 1083-1095
157. Kronik N, Kogan Y, Vainstein V, Agur Z (2008) Improving alloreactive CTL immunotherapy for malignant gliomas using a simulation model of their interactive dynamics. Cancer Immunol Immunother 57(3):425-439
158. Ribba B, Colin T, Schnell S (2006) A multiscale mathematical model of cancer, and its use in analyzing irradiation therapies. Theor Biol Med Model 3:7
159. Clarke DC, Liu X (2008) Decoding the quantitative nature of TGF-beta/Smad signaling. Trends Cell Biol 18(9):430-442
160. Wilson S, Levy D (2012) A mathematical model of the enhancement of tumor vaccine efficacy by immunotherapy. Bull Math Biol 74(7):1485-1500
161. Woelke AL, Murgueitio MS, Preissner R (2010) Theoretical modeling techniques and their impact on tumor immunology. Clin Dev Immunol 2010:271794
162. Kirschner D, Panetta JC (1998) Modeling immunotherapy of the tumor-immune interaction. J Math Biol 37(3):235-252
163. de Pillis LG, Gu W, Radunskaya AE (2006) Mixed immunotherapy and chemotherapy of tumors: modeling, applications and biological interpretations. J Theor Biol 238(4):841-862
164. de Pillis L, Fister KR, Gu W, Collins C, Daub M, Gross D, Moore J, Preskill B (2009) Mathematical model creation for cancer chemo-immunotherapy. Computational and Mathematical Methods in Medicine. Hindawi Publishing Corporation, pp 165-184
165. Iwami S, Haeno H, Michor F (2012) A race between tumor immunoescape and genome maintenance selects for optimum levels of (epi)genetic instability. PLoS Comput Biol 8(2):e1002370
166. Kogan Y, Fory U, Shukron O, Kronik N, Agur Z (2010) Cellular Immunotherapy for high grade gliomas: mathematical analysis deriving efficacious infusion rates based on patient requirements. SIAM J Appl Math 70(6):1953
167. Trisilowati, Mallet DG (2012) In silico experimental modeling of cancer treatment. ISRN Oncol 2012:828701
168. Jara-Lazaro AR, Thamboo TP, Teh M, Tan PH (2010) Digital pathology: exploring its applications in diagnostic surgical pathology practice. Pathology 42(6):512-518
169. Cancer Genome Atlas Network (2012) Comprehensive molecular characterization of human colon and rectal cancer. Nature 487(7407):330-337